Biotechnology Sector

Find out if the biotech companies Labiotech designated as the ones to keep an eye on in 2024 held up to our expectation in 2025. The post Biotech stars of 2024, did they shine or fade in 2025?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. It is the fourth wave of job cuts from the Roche subsidiary in the last 15 months.

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that it expects its troubled R&D partner to meet its financial obligations.

The FDA has begun accepting applications for a priority pathway designed to slash review times to one to two months, giving developers of medicines that align with U.S. national health priorities a fast track to market.

After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach.

Meet the most successful biotech companies in Belgium, a country that makes a huge contribution to the biotech industry.  The post Seven biotechs in Belgium making leaps in the clinic  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer vaccine candidate rather than its older sibling.

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to receive complete response letters from the new-look agency. Investors sent the biotech’s share price down 76% to below $3 in premarket trading.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus pipeline beyond mRNA.

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the number of nightly breath-stopping events by 46.8%, hitting the test's primary endpoint.

The NATO Innovation Fund has invested in the first biotech. What’s got NATO interested, and how will this change the future of healthcare? The post NATO Innovation Fund invests in first biotech: what’s to come? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle muscular dystrophy (LGMD) trials, while also revoking the biopharma’s gene therapy platform technology designation.

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos Therapeutics after the failure of its GSK-partnered TIGIT drug led the company to begin winding down.

Alkermes has reported a midphase win in narcolepsy type 1, keeping up the pressure on Takeda’s near-approval rival for the blockbuster opportunity.

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs.

Roche’s hopes of getting astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in a phase 3 study.

A phase 2 trial of Cloudbreak Pharma’s eye disease prospect CBT-004 has hit its primary endpoint, teeing the company up to advance the candidate and talk to the FDA about the route to approval.

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided it’s time to shut up shop completely.

In a transformative leap that challenges longstanding constraints in energy conversion technology, researchers have unveiled a groundbreaking design paradigm for solid oxide cells (SOCs) that dramatically enhances their efficiency, durability, and structural integration. Traditional SOCs, fundamental devices capable of interconverting chemical energy and electricity at high temperatures, have been largely limited by planar, two-dimensional (2D)

In the relentless battle between crops and pathogens, understanding the genetic basis of disease resistance remains one of the most formidable challenges in plant biology. Sorghum, a staple cereal crop integral to global food security, is no exception. Among the myriad diseases threatening its yield, grain mold—a complex fungal affliction—stands out for its detrimental impact

In a groundbreaking study that promises to redefine how we understand immune-mediated kidney disease, researchers have unveiled PathoPlex, a cutting-edge multiplexing technology that offers unprecedented insight into the cellular and molecular mechanisms driving renal pathology. By harnessing the power of spatially resolved, high-dimensional imaging, this innovative platform allows scientists to map disease processes at a

In the relentless pursuit to unravel the complex mechanisms underpinning type 2 diabetes (T2D), a groundbreaking study has emerged that shines an unprecedented light on the immune dysregulation at its core. Traditionally recognized as a metabolic disorder characterized by insulin resistance and chronic hyperglycemia, T2D is increasingly understood to be driven by intricate immunological disturbances,

A biotech incubator at the University of California, Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes.

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy. The post Hyderabad’s Genome Valley, biopharma’s scale-up hub appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Sail Biomedicines is shrinking its crew for the second time this year. The Flagship Pioneering-backed biotech is laying off about 36 employees as the company sharpens its focus on immunology, a company spokesperson confirmed to Fierce Biotech.

Following a tumultuous week for Sarepta Therapeutics, the biotech has confirmed that a third patient has died after receiving one of the company’s gene therapies. On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

This week, I talked to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation. The post Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

It looks like your input was cut off at the end. From the text you provided, here is a summary and some points about the study: Summary of the Study: Background: ValveNet is an AI-ECG model designed to detect moderate or greater left-sided valvular heart disease (VHD) — specifically aortic stenosis, aortic regurgitation, and mitral

In the intricate machinery of life, ribosomes stand as the quintessential molecular factories responsible for translating genetic information into functional proteins. These macromolecular complexes orchestrate the decoding of messenger RNA (mRNA) into polypeptide chains, a process fundamental to all cellular organisms. Despite the long evolutionary journey and the structural variations observed across different domains of

In the realm of soft matter physics and materials science, the ability to manipulate liquids into dynamically reconfigurable shapes holds immense promise for transformative applications. A recent breakthrough by Roh, Ha, and Abbott unveils a biphasic liquid system capable of reversible, long-lived microdomain transformations driven by electric fields. This discovery transcends prior limitations imposed by

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a massive overhaul of its organization. The company’s chief customer officer Dallan Murray is headed out the door, to be replaced by Patrick Moss, formerly senior vice president of U.S. market access and sales and now chief commercial officer.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease. The post New horizons in sickle cell disease treatment: Promising therapies on the way appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens and protect against emerging public health threats.

In a groundbreaking study that promises to reshape our understanding of soil ecosystems, researchers have unveiled how subtle shifts in microbial communities can signal impending environmental upheavals. The investigation delves deep into soil microbiomes, revealing that compositional changes among bacterial taxa precede critical transitions in soil functionality driven by pH fluctuations. This discovery opens new

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to "pursue new professional opportunities."

In the evolving landscape of brain-wide association studies, a recent investigation underscores a pivotal strategy that intriguingly challenges conventional wisdom: extending the duration of functional magnetic resonance imaging (fMRI) scans not only sharpens predictive accuracy but also reduces overall research costs. This paradigm shift confronts the traditional notion that shorter scans paired with larger sample

In the relentless pursuit of energy-efficient and environmentally benign light-emitting technologies, researchers have turned their attention toward novel hybrid materials that can revolutionize solid-state lighting. In a compelling advance, a team of scientists has unveiled a non-toxic copper–iodide-based hybrid that exhibits near-perfect photoluminescence quantum yield paired with stable, deep-blue emission. This breakthrough not only promises

In the depths of the Early Jurassic seas, one marine predator reigned supreme not only through sheer size but also through unparalleled adaptations for stealth. The genus Temnodontosaurus, a colossal ichthyosaur that sometimes grew beyond ten meters, occupied apex trophic positions within its ecosystem. Combining formidable physicality with specialized sensory and locomotory traits, these ancient

In the relentless battle between plants and the myriad pathogens that threaten global agriculture, scientists have long sought innovative ways to bolster plant immune systems. Recent breakthroughs now herald a promising frontier in crop protection: the strategic remodeling of nucleotide-binding and leucine-rich-repeat immune receptors, or NLRs, to confer broad-spectrum and durable disease resistance. A new

In a groundbreaking advancement that could transform the landscape of nano-optics and photonics, researchers have reported the observation of long-range hyperbolic polaritons on a non-hyperbolic crystal surface. This remarkable finding challenges the long-standing paradigm that hyperbolic polariton phenomena are exclusive to hyperbolic crystals—materials known for their anisotropic permittivity with tensor components of opposite signs. The

In a groundbreaking exploration of gut microbial ecology, recent research reveals how non-antibiotic drugs can disrupt the delicate balance of colonization resistance against harmful pathogens. This study sheds light on the complex interplay between a pathogen and its closely related microbial competitors within the gut environment, exposing how drug-induced perturbations tilt this balance in favor

Childhood obesity has become one of the most pressing public health issues of the 21st century, with far-reaching implications for individuals and societies worldwide. While body mass index (BMI) is the conventional metric for assessing obesity in both clinical and research settings, relying on cross-sectional BMI data at a single point in time often masks

In a groundbreaking study poised to reshape our understanding of medication impacts on human health, researchers have unveiled compelling evidence that common prescription drugs can significantly alter the gut microbiome and, consequently, influence susceptibility to intestinal infections. This research, encompassing a massive cohort of over one million individuals tracked meticulously for 15 years, sheds light

A revolutionary study published recently in Nature unveils the hidden dynamics of genome doubling in ovarian cancer, unraveling how this dramatic genetic event fuels tumor evolution by accelerating chromosomal instability. The findings offer unprecedented insights into the mechanisms through which whole genome doubling (WGD) reshapes cancer cell populations, ultimately influencing tumor progression and immune interactions.

In recent years, the pursuit of enantiopure compounds has emerged as a cornerstone in organic synthesis, primarily due to the critical roles that chiral molecules play in biological systems. The three-dimensional arrangement of atoms around chiral centers can dramatically influence a molecule’s interaction with biological targets, thus affecting pharmacodynamics, pharmacokinetics, and overall therapeutic efficacy. This

In the vast tapestry of life’s evolution, few biological innovations have altered the trajectory of existence as profoundly as aerobic metabolism. Emerging billions of years ago, it harnessed the energy-rich bounty of oxygen, catalyzing a cascade of complexity that ultimately led to the rise of multicellular organisms. This evolutionary milestone, intricately tied to two major

In a groundbreaking advancement at the intersection of ultrafast spectroscopy and X-ray science, researchers have unveiled a novel technique that sharply enhances resolution beyond the fundamental limitations of current X-ray free-electron laser (XFEL) sources. This cutting-edge development exploits the stochastic nature of self-amplified spontaneous emission (SASE) in XFEL pulses to achieve super-resolution stimulated X-ray Raman

Discover eight rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them. The post Eight rare autoimmune diseases biotechs are fighting to treat appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Regulatory expert shares how early planning and FDA engagement can speed oncology approval

Concentra Biosciences is buying struggling biotechs and its portfolio has been growing rapidly in 2025. Learn about what it has been up to this past year. The post Serial acquirer Concentra Biosciences on a buyout spree in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Here are 51 great biotech books for this summer 2025 that are bound to get you hooked. From sci-fi to the nitty-gritties of biotech, we’ve got you covered! The post Top biotech books of all time appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Turnstone Biologics is being acquired by royalty aggregator Xoma Royalty. Discover how royalty deals are shaping the biopharma industry. The post XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

This week we talk about Congenital Adrenal Hyperplasia and how OMass Therapeutics is approaching it with the company CEO, Ros Deegan. The post How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms. The post Radiopharma’s new wave: Nuclidium and Actithera raise the stakes  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...

Here are your events for the week Sunday, September 3 Oakland, CA, USA – Open Insulin Lab Day  Work on...

Here are your events for the remainder of the week Monday, August 28 Oakland, CA, USA – Plant Bio Group...

Here are your DIYbio events for the week Sunday, August 20 Cincinnati, OH, USA – Science Book Club – The...

Here are your DIYbio events for the remainder of the week Monday, August 14 Brooklyn, NY, USA – Biotextiles: Grow...

Here are your events for the week. Sunday, August 6 Brooklyn, NY, USA – Biotech Crash Course Introductory intense hands-on...

Here are your DIYbio events for the week of July 30 Sunday, July 30 Brooklyn, NY, USA – Summer Ferments  ...

Here are your DIYbio events for remainder of the week Monday, January 9 Brooklyn, NY, USA Open Night: PCR &...

Here are your DIYbio events for the week On Sunday Durham has Edward Richards giving a talk  “Current Issues In...

Here are your DIYbio events for the week. On Sunday, Brooklyn begins its Biotechnology Crash Course, Cambridge has a series...